Genome Engineering Market Synopsis

Genome Engineering Market Size Was Valued at USD 7.7 Billion in 2023, and is Projected to Reach USD 30.9 Billion by 2032, Growing at a CAGR of 16.7% From 2024-2032.

The genome engineering market is therefore centred on those technologies and methodologies that seek to alter the genetic structure. These include methods like CRISPR-Cas9, transcription activator-like effector nucleases (TALENs), zinc finger nucleases (ZFNs), and recombinant DNA technology, which enables putting precise changes in the DNA sequences. Genome engineering is a very important tool in number of sectors such as agriculture, biotechnology, pharmaceutical and medicine. As a method that enhances gene editing with superior accuracy it benefits researchers in realizing their gene therapy, improving crop variety and GMOs production. A seemingly inevitable development in this field is the increasing requirements for personalised biological products and the need for new strategies in the treatment of diseases thus spearheading the growth of this market.

• The growth has been realized especially in the past years by the improved biotechnology and the research and development investment. With the increasing demand for therapies of genetic diseases, then there has been an increase in adoption of genome engineering technologies. It is used in many industries such as agriculture in which their use can increase crops resistance and their productivity and pharmaceuticals where their use can assist in the production of medicine to suit particular persons. Besides, the higher incidence rates of genetic diseases and the growing requirement for effective disease control in modern society have increased the emphasis on genome editing tools. Therefore the market is expected to grow at a fast pace in the future with developing innovations and also a strong pipeline of products available.
• Moreover, cooperation between academic institutions, research entities and biotechnology firms is enabling the progress of genome engineering. Such collaborations underlie the possibility of using genetic changes in managing such diseases and dealing with food insecurity. Laws and policies are also changing with the increasing number of genome-engineered products that are now in the market with a view of creating acceptance in commercial market, especially in agriculture and health sectors. The rise in consumer acceptance of genetically modified crops and the concern shown by consumers about the benefits associated with genetically modified crops both are the other main factors that driving the growth of the market. Consequently, it is forecasted that genome engineering market will be experiencing compound annual growth rate (CAGR) of above percentage involve in the next coming years due to rising demand and progressive development of investment and technology.

Genome Engineering Market Trend Analysis

Growing Adoption of CRISPR Technology

• The largest share of this market has been observed to be going for genome engineering with CRISPR being one of the most popular among the customers. CRISPR/Cas9 one of the cutting-edge genetic engineering tools in the field of biotechnology, it is easy to use, rapid and multi- functional platform. More so, scientists and engineers have expanded its use as a multipurpose tool in gene therapy, bioengineering, and food crops modification. Due to its simplicity and cheaper costs as compared to other methods, CRISPR has become favorite tool to many scientists and biotechnologists. Thus, predicting that, as more companies pour resources in to the development of CRISPR based solutions, the field of genetic engineering will only progress further unlocking possibilities for medical applications as well as crop and environmental improvements. The increasing trend of embracing individualized drugs and regenerative treatments also accelerates the acceptance of CRISPR technology as a leading actor in the genome engineering market.

Expanding Applications in Healthcare

• The market of genome engineering is an important area in healthcare with some great potential in context of the targeted treatment for a range of genetic diseases. This project aims at developing novel therapeutic approaches which that can be effective in conditions that are on the rise such as cancer, cystic fibrosis and muscular dystrophy. Genome engineering technologies help scientists create accurate GE strategies for treatment or prevention of diseases for which there heretofore were no known cure. More importantly genome engineering techniques have fostered further developments in gene therapy that provides better treatment option, which will have better outcome for patients. The partnership between biotechnology firms and healthcare institutions is expected to drive creation of new genome-engineered therapies thereby, broadening the market. Thirdly, with increased backing from the regulatory authorities, the opportunities for developing and monetizing such treatments are expected to grow rapidly, presenting tremendous potential for thriving genome engineering market players.

Genome Engineering Market Segment Analysis:

Genome Engineering Market Segmented on the basis of Technology, Mode and end user.

By technology, the ZFN segment is projected to grow at a notable CAGR of 17.34% during the forecast period

• Some of the major segments in the genomic engineering market include Transcription Activator-Like Effector Nuclease (TALEN), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR), and Zinc Finger Nuclease (ZFN) market, especially in the ZFN segment, there is a growing CAGR expected between 2018 and 2023 at 17.34%. This important growth can be explained by the expanding usage areas of ZFN technology in such segments as gene therapy, agriculture, and pharmaceutical industries.
• Because ZFNs are only designed to bind to specific DNA targets and can be engineered to cleave a specific DNA sequence with incredible accuracy, it makes them an important tool for researchers and developers who want to fine tune specific genotypes. Indeed, the increasing rates of genetic diseases as well as enhanced requirements for new treatment are driving developments in ZFN technology. Because ZFN holds much promise for creating targeted solutions to many genetic problems, its usage is likely to spread among more firms, thus spurring the overall development of this segment. Also, new designs and optimizing strategies are improving the ability of ZFN to perform its goals, making it a favored method among genome engineering tools.

By mode, the contract segment led the market in 2023

• Data by the contract segment showed that it was the biggest mode of the genome engineering market in 2023, which was due to the ranking preference of organizations for outsourcing research and development contracts. This mode of engagement provides companies with an opportunity to tap into dedicated professional knowledge and tools in outsourcing service providers such as CROs. As the projects in genome engineering become more challenging, and the requirement for shortened cycle times and lower costs arises, more organizations turn to outside collaborators.
• Contract services enable organisations to leverage the latest tools and techniques while avoiding comprehensively high internal setup costs. Also, the contract segment reduces the time it takes to develop new cycles such that CROs exist with set procedures and staff members who fully understand the legal restraints. Consequently, it is considered that the contract segment will remain the market leader, responding to the needs and offering knowledge to the organizations that seek to develop their genome engineering programs.

Genome Engineering Market Regional Insights:

Asia Pacific is Expected to Dominate the Market Over the Forecast period

• In 2023 the global market share belonged to North America, which holds approximately 40% of the genome engineering market. Several factors make this leadership possible, these include important players in biotechnology industries, high research investments and development plus well-developed facilities for genomic studies. The United States can be especially credited for experimental and technological developments in this area as many research-based universities and institutes from the country have been actively involved in development of new research of genome engineering.
• Furthermore, the political environment in North America is relatively friendly to the design and marketing of genome-engineered products. Moreover, target disease rate of genetic disorders and the powerful trend for precise medicine are also boosting the market growth in this region. As the global stakeholders demands various application of genome editing, North America is likely to remain as a dominant region in the market for genome engineering.

Active Key Players in the Genome Engineering Market

• Agilent Technologies (USA)
• Bluebird Bio (USA)
• Boehringer Ingelheim (Germany)
• Caribou Biosciences (USA)
• Cellectis (France)
• CRISPR Therapeutics (Switzerland)
• Editas Medicine (USA)
• Ginkgo Bioworks (USA)
• Horizon Discovery (UK)
• Intellia Therapeutics (USA)
• Qiagen (Netherlands)
• Regeneron Pharmaceuticals (USA)
• SGI-DNA (USA)
• Thermo Fisher Scientific (USA)
• Zymergen (USA)
• Other key Players

Chapter 1: Introduction
 1.1 Scope and Coverage

Chapter 2:Executive Summary

Chapter 3: Market Landscape
 3.1 Market Dynamics
  3.1.1 Drivers
  3.1.2 Restraints
  3.1.3 Opportunities
  3.1.4 Challenges
 3.2 Market Trend Analysis
 3.3 PESTLE Analysis
 3.4 Porter's Five Forces Analysis
 3.5 Industry Value Chain Analysis
 3.6 Ecosystem
 3.7 Regulatory Landscape
 3.8 Price Trend Analysis
 3.9 Patent Analysis
 3.10 Technology Evolution
 3.11 Investment Pockets
 3.12 Import-Export Analysis

Chapter 4: Genome Engineering Market by Technology
 4.1 Genome Engineering Market Snapshot and Growth Engine
 4.2 Genome Engineering Market Overview
 4.3 (CRISPR)/Cas9
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 (CRISPR)/Cas9: Geographic Segmentation Analysis
 4.4 ZFN
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 ZFN: Geographic Segmentation Analysis
 4.5 Meganuclease
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Meganuclease: Geographic Segmentation Analysis
 4.6 TALENs/MegaTALs
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 TALENs/MegaTALs: Geographic Segmentation Analysis
 4.7 Others
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 Others: Geographic Segmentation Analysis

Chapter 5: Genome Engineering Market by Mode
 5.1 Genome Engineering Market Snapshot and Growth Engine
 5.2 Genome Engineering Market Overview
 5.3 Contract
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Contract: Geographic Segmentation Analysis
 5.4 In-house
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 In-house: Geographic Segmentation Analysis

Chapter 6: Genome Engineering Market by End User
 6.1 Genome Engineering Market Snapshot and Growth Engine
 6.2 Genome Engineering Market Overview
 6.3 Biotechnology & Pharmaceutical Companies
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Biotechnology & Pharmaceutical Companies: Geographic Segmentation Analysis
 6.4 Contract Research Organizations
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Contract Research Organizations: Geographic Segmentation Analysis
 6.5 Academic & Government Research Institutes
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Academic & Government Research Institutes: Geographic Segmentation Analysis

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Benchmarking
  7.1.2 Genome Engineering Market Share by Manufacturer (2023)
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Mergers and Acquisitions
  
 7.2 AGILENT TECHNOLOGIES (USA)
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Role of the Company in the Market
  7.2.5 Sustainability and Social Responsibility
  7.2.6 Operating Business Segments
  7.2.7 Product Portfolio
  7.2.8 Business Performance
  7.2.9 Key Strategic Moves and Recent Developments
  7.2.10 SWOT Analysis
 7.3 BLUEBIRD BIO (USA)
 7.4 BOEHRINGER INGELHEIM (GERMANY)
 7.5 CARIBOU BIOSCIENCES (USA)
 7.6 CELLECTIS (FRANCE)
 7.7 CRISPR THERAPEUTICS (SWITZERLAND)
 7.8 EDITAS MEDICINE (USA)
 7.9 GINKGO BIOWORKS (USA)
 7.10 HORIZON DISCOVERY (UK)
 7.11 INTELLIA THERAPEUTICS (USA)
 7.12 QIAGEN (NETHERLANDS)
 7.13 REGENERON PHARMACEUTICALS (USA)
 7.14 SGI-DNA (USA)
 7.15 THERMO FISHER SCIENTIFIC (USA)
 7.16 ZYMERGEN (USA)
 7.17 OTHER ACTIVE PLAYERS

Chapter 8: Global Genome Engineering Market By Region
 8.1 Overview
 8.2. North America Genome Engineering Market
  8.2.1 Key Market Trends, Growth Factors and Opportunities
  8.2.2 Top Key Companies
  8.2.3 Historic and Forecasted Market Size by Segments
  8.2.4 Historic and Forecasted Market Size By Technology
  8.2.4.1 (CRISPR)/Cas9
  8.2.4.2 ZFN
  8.2.4.3 Meganuclease
  8.2.4.4 TALENs/MegaTALs
  8.2.4.5 Others
  8.2.5 Historic and Forecasted Market Size By Mode
  8.2.5.1 Contract
  8.2.5.2 In-house
  8.2.6 Historic and Forecasted Market Size By End User
  8.2.6.1 Biotechnology & Pharmaceutical Companies
  8.2.6.2 Contract Research Organizations
  8.2.6.3 Academic & Government Research Institutes
  8.2.7 Historic and Forecast Market Size by Country
  8.2.7.1 US
  8.2.7.2 Canada
  8.2.7.3 Mexico
 8.3. Eastern Europe Genome Engineering Market
  8.3.1 Key Market Trends, Growth Factors and Opportunities
  8.3.2 Top Key Companies
  8.3.3 Historic and Forecasted Market Size by Segments
  8.3.4 Historic and Forecasted Market Size By Technology
  8.3.4.1 (CRISPR)/Cas9
  8.3.4.2 ZFN
  8.3.4.3 Meganuclease
  8.3.4.4 TALENs/MegaTALs
  8.3.4.5 Others
  8.3.5 Historic and Forecasted Market Size By Mode
  8.3.5.1 Contract
  8.3.5.2 In-house
  8.3.6 Historic and Forecasted Market Size By End User
  8.3.6.1 Biotechnology & Pharmaceutical Companies
  8.3.6.2 Contract Research Organizations
  8.3.6.3 Academic & Government Research Institutes
  8.3.7 Historic and Forecast Market Size by Country
  8.3.7.1 Bulgaria
  8.3.7.2 The Czech Republic
  8.3.7.3 Hungary
  8.3.7.4 Poland
  8.3.7.5 Romania
  8.3.7.6 Rest of Eastern Europe
 8.4. Western Europe Genome Engineering Market
  8.4.1 Key Market Trends, Growth Factors and Opportunities
  8.4.2 Top Key Companies
  8.4.3 Historic and Forecasted Market Size by Segments
  8.4.4 Historic and Forecasted Market Size By Technology
  8.4.4.1 (CRISPR)/Cas9
  8.4.4.2 ZFN
  8.4.4.3 Meganuclease
  8.4.4.4 TALENs/MegaTALs
  8.4.4.5 Others
  8.4.5 Historic and Forecasted Market Size By Mode
  8.4.5.1 Contract
  8.4.5.2 In-house
  8.4.6 Historic and Forecasted Market Size By End User
  8.4.6.1 Biotechnology & Pharmaceutical Companies
  8.4.6.2 Contract Research Organizations
  8.4.6.3 Academic & Government Research Institutes
  8.4.7 Historic and Forecast Market Size by Country
  8.4.7.1 Germany
  8.4.7.2 UK
  8.4.7.3 France
  8.4.7.4 Netherlands
  8.4.7.5 Italy
  8.4.7.6 Russia
  8.4.7.7 Spain
  8.4.7.8 Rest of Western Europe
 8.5. Asia Pacific Genome Engineering Market
  8.5.1 Key Market Trends, Growth Factors and Opportunities
  8.5.2 Top Key Companies
  8.5.3 Historic and Forecasted Market Size by Segments
  8.5.4 Historic and Forecasted Market Size By Technology
  8.5.4.1 (CRISPR)/Cas9
  8.5.4.2 ZFN
  8.5.4.3 Meganuclease
  8.5.4.4 TALENs/MegaTALs
  8.5.4.5 Others
  8.5.5 Historic and Forecasted Market Size By Mode
  8.5.5.1 Contract
  8.5.5.2 In-house
  8.5.6 Historic and Forecasted Market Size By End User
  8.5.6.1 Biotechnology & Pharmaceutical Companies
  8.5.6.2 Contract Research Organizations
  8.5.6.3 Academic & Government Research Institutes
  8.5.7 Historic and Forecast Market Size by Country
  8.5.7.1 China
  8.5.7.2 India
  8.5.7.3 Japan
  8.5.7.4 South Korea
  8.5.7.5 Malaysia
  8.5.7.6 Thailand
  8.5.7.7 Vietnam
  8.5.7.8 The Philippines
  8.5.7.9 Australia
  8.5.7.10 New Zealand
  8.5.7.11 Rest of APAC
 8.6. Middle East & Africa Genome Engineering Market
  8.6.1 Key Market Trends, Growth Factors and Opportunities
  8.6.2 Top Key Companies
  8.6.3 Historic and Forecasted Market Size by Segments
  8.6.4 Historic and Forecasted Market Size By Technology
  8.6.4.1 (CRISPR)/Cas9
  8.6.4.2 ZFN
  8.6.4.3 Meganuclease
  8.6.4.4 TALENs/MegaTALs
  8.6.4.5 Others
  8.6.5 Historic and Forecasted Market Size By Mode
  8.6.5.1 Contract
  8.6.5.2 In-house
  8.6.6 Historic and Forecasted Market Size By End User
  8.6.6.1 Biotechnology & Pharmaceutical Companies
  8.6.6.2 Contract Research Organizations
  8.6.6.3 Academic & Government Research Institutes
  8.6.7 Historic and Forecast Market Size by Country
  8.6.7.1 Turkey
  8.6.7.2 Bahrain
  8.6.7.3 Kuwait
  8.6.7.4 Saudi Arabia
  8.6.7.5 Qatar
  8.6.7.6 UAE
  8.6.7.7 Israel
  8.6.7.8 South Africa
 8.7. South America Genome Engineering Market
  8.7.1 Key Market Trends, Growth Factors and Opportunities
  8.7.2 Top Key Companies
  8.7.3 Historic and Forecasted Market Size by Segments
  8.7.4 Historic and Forecasted Market Size By Technology
  8.7.4.1 (CRISPR)/Cas9
  8.7.4.2 ZFN
  8.7.4.3 Meganuclease
  8.7.4.4 TALENs/MegaTALs
  8.7.4.5 Others
  8.7.5 Historic and Forecasted Market Size By Mode
  8.7.5.1 Contract
  8.7.5.2 In-house
  8.7.6 Historic and Forecasted Market Size By End User
  8.7.6.1 Biotechnology & Pharmaceutical Companies
  8.7.6.2 Contract Research Organizations
  8.7.6.3 Academic & Government Research Institutes
  8.7.7 Historic and Forecast Market Size by Country
  8.7.7.1 Brazil
  8.7.7.2 Argentina
  8.7.7.3 Rest of SA

Chapter 9 Analyst Viewpoint and Conclusion
9.1 Recommendations and Concluding Analysis
9.2 Potential Market Strategies

Chapter 10 Research Methodology
10.1 Research Process
10.2 Primary Research
10.3 Secondary Research